Skip to content
drillr.ai

APGE

Apogee Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$134.15+0.11%

Price as of Jul 20, 2026

APGE news

Apogee Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  2. $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRBG, RMAX, GBCS, and APGE

    $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRBG, RMAX, GBCS, and APGE PR Newswire NEW YORK, July 14, 2026 NEW YORK, July 14, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4731383-1&h=960342029&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde) with Monteverde & Associates PC (https://edge

    PR Newswire ·

  3. Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?

    Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 6, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible

    PR Newswire ·

  4. $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--AVB, APGE, TMHC, and LPRO

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--AVB, APGE, TMHC, and LPRO PR Newswire NEW YORK, July 6, 2026 NEW YORK, July 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4725789-1&h=3145518828&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde) with Monteverde & Associates PC (https://edge.prne

    PR Newswire ·

  5. Are APGE, INVE, CBAN, FSRL Obtaining Fair Deals for their Shareholders?

    Are APGE, INVE, CBAN, FSRL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 2, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsibl

    PR Newswire ·

  6. SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS PR Newswire NEW YORK, July 2, 2026 NEW YORK, July 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4724546-2&h=3914342227&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (https://edge.prn

    PR Newswire ·

  7. Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders

    MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apogee (NASDAQ: APGE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with CRH. Click here (https://www.globenewswire.com/Tracker?data=G3hF7lwp8qpB3htbYoVFcDBLMBSJUT-JMhqd3TYZ0ZjTTHZA1IjTd0CI56Dkkgt6tgFJEy8nqaPdWDoR6drstF4gwUXnhVJAI_LEHdB6-EZHyx5Zoj27JDduEjY-baV-) to learn how to join our investigation and obtain additional information or contact us at gademi@ademila

    Globe Newswire ·

  8. Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

    Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsib

    PR Newswire ·

  9. Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders

    Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Halpe

    Globe Newswire ·

  10. Are ACA, CZR, APGE Obtaining Fair Deals for their Shareholders?

    Are ACA, CZR, APGE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 22, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for o

    PR Newswire ·

  11. SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apogee Therapeutics, Inc. (NASDAQ: APGE)

    SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apogee Therapeutics, Inc. (NASDAQ: APGE) PR Newswire NEW YORK, June 22, 2026 NEW YORK, June 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4716635-2&h=1240683207&u=https%3A%2F%2Fprofiles.superlawyers.com%2Fnew-york%2Fnew-york%2Flawyer%2Fjuan-e-monteverde%2Fb861d99b-d20f-4376-92c4-2996390bacbc.html&a=Juan+Monteverde)  with Monteverde & Associates PC (https:

    PR Newswire ·

  12. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

    BALA CYNWYD, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Apogee Therapeutics, Inc. (Nasdaq – APGE) Under the terms of the Merger Agreement, Apogee will be acquired by AbbVie (NYSE – ABBV) for $135.11 per share in cash

    Globe Newswire ·

  13. APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

    APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you

    Business Wire ·

  14. AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

    AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio PR Newswire NORTH CHICAGO, Ill. and SAN FRANCISCO and BOSTON, June 22, 2026 * Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases * Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with

    PR Newswire ·

  15. Apogee Therapeutics to Participate in Upcoming June Conferences

    SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Jefferies Global Healthcare Conference  Date: Wednesday, June 3, 2026 Fireside Time: 11:40 a.m. ET Goldman Sachs 47(th) Annual Global Healthcare Conference Date: Wednesday, June 10, 2026 Fireside Time: 9:20 a.m. ET A live and archived webcast of the fireside chats will be available via the News &

    Globe Newswire ·

  16. Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

    Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt  Combined with company's current total cash of $1.3 billion, this transaction positions Apogee to achieve a self-sustainable financial profile through commercialization of zumilokibart without need for future equity financing Apogee to host webcast with the APEX Phase 2 Part B results today at 8:00 a.m. Eastern Time SAN FRANCISCO and

    Globe Newswire ·

  17. Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

    APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart was well tolerated with a safety profile consistent with other agents in class Strategic financing collaboration with Blackstone Life Sciences announced today expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE Results support pipeline-in

    Globe Newswire ·

  18. Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

    SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to d

    Globe Newswire ·

  19. Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

    SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 750,000 additiona

    Globe Newswire ·

  20. Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

    SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from

    Globe Newswire ·